Spindle cell oncocytoma of the pituitary gland.
CN = cranial nerve
CNS = central nervous system
EMA = epithelial membrane antigen
GFAP = glial fibrillary acidic protein
GTR = gross-total resection
OSH = outside hospital
S100 = S100 protein
SCO = spindle cell oncocytoma
TS = transsphenoidal
TTF-1 = thyroid transcription factor 1
WHO = World Health Organization
neurosurgery
pituitary surgery
spindle cell oncocytoma
transsphenoidal
Journal
Journal of neurosurgery
ISSN: 1933-0693
Titre abrégé: J Neurosurg
Pays: United States
ID NLM: 0253357
Informations de publication
Date de publication:
01 08 2019
01 08 2019
Historique:
received:
23
01
2018
accepted:
27
04
2018
pubmed:
30
11
2018
medline:
21
11
2019
entrez:
29
11
2018
Statut:
epublish
Résumé
The authors report the diagnosis, management, and outcomes of 6 cases of spindle cell oncocytoma (SCO) in an effort to guide clinical diagnosis and management of these uncommon lesions. This study is a retrospective review of cases involving adult patients who underwent resection of pituitary lesions at the authors' institutions between January 2000 and October 2017. The authors identified patients with histopathological confirmation of SCO and collected clinical data, including preoperative, perioperative, and postoperative management, complications, and outcomes. Six patients with SCO were identified. Clinical findings at initial presentation included visual disturbances, dizziness, and headache. All patients underwent resection. Four resections were initially performed by the transsphenoidal approach, and 2 resections were performed by craniotomy at an outside institution with subsequent transsphenoidal reoperations. Neither necrosis nor increased mitotic activity was seen in the tumor samples. All samples stained positive for S100 protein and thyroid transcription factor 1 and negative for glial fibrillary acidic protein and pituitary hormones. Five of the samples stained positive for epithelial membrane antigen. The average MIB-1 index was 8.3% (range 2-17). Postoperatively, 3 of the 6 patients received further treatment for progression of residual tumor or for recurrence, 2 have stable residual tumor, and 1 has had no recurrence after gross-total resection. Two patients developed postoperative complications of transient sixth cranial nerve palsy and diplopia. There were no other complications. SCO poses both a diagnostic and therapeutic challenge. These tumors are often initially misdiagnosed as nonfunctional pituitary adenomas because of their sellar location and nonspecific symptomatology. Postoperatively, SCO must also be distinguished from other neoplasms of the posterior pituitary gland through histopathological examination. Resection of SCO can be challenging, given its highly vascular and adherent nature. Long-term follow-up is critical, as the tumor is associated with higher recurrence and progression rates compared to other benign neoplasms of the sella.
Identifiants
pubmed: 30485213
doi: 10.3171/2018.4.JNS18211
pii: 2018.4.JNS18211
pmc: PMC6486883
mid: NIHMS1020528
doi:
pii:
Types de publication
Case Reports
Journal Article
Research Support, N.I.H., Extramural
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
517-525Subventions
Organisme : NCI NIH HHS
ID : T32 CA009001
Pays : United States
Organisme : NHLBI NIH HHS
ID : T32 HL007627
Pays : United States
Références
Neurol Med Chir (Tokyo). 2012;52(8):594-8
pubmed: 22976144
J Med Case Rep. 2011 Feb 14;5:64
pubmed: 21320334
AJNR Am J Neuroradiol. 2011 Dec;32(11):2067-72
pubmed: 21960498
Clin Imaging. 2014 Jul-Aug;38(4):499-504
pubmed: 24721021
J Neuropathol Exp Neurol. 2009 May;68(5):482-8
pubmed: 19525896
Clin Neuropathol. 2009 Mar-Apr;28(2):91-5
pubmed: 19353839
Am J Surg Pathol. 2013 Nov;37(11):1694-9
pubmed: 23887161
Acta Neuropathol. 2007 Aug;114(2):97-109
pubmed: 17618441
J Clin Neurosci. 2017 May;39:39-44
pubmed: 28286028
Brain Pathol. 2007 Jul;17(3):304-7
pubmed: 17598822
J Neurooncol. 2011 Jan;101(1):145-54
pubmed: 20495848
Clin Neuropathol. 2009 Jul-Aug;28(4):303-8
pubmed: 19642510
Am J Case Rep. 2017 Aug 17;18:894-901
pubmed: 28814709
Ann Clin Lab Sci. 2012 Spring;42(2):123-9
pubmed: 22585606
Clin Radiol. 2016 Sep;71(9):937.e5-937.e11
pubmed: 27234433
World Neurosurg. 2015 Oct;84(4):899-905
pubmed: 26008142
Brain Tumor Pathol. 2011 Oct;28(4):359-64
pubmed: 21833579
Oncotarget. 2016 Jun 14;7(24):37054-37063
pubmed: 27175596
Endocr Pathol. 2017 Sep;28(3):228-243
pubmed: 28766057
J Clin Neurosci. 2017 Sep;43:134-146
pubmed: 28668473
Clin Neurol Neurosurg. 2012 Apr;114(3):267-71
pubmed: 22071206
Pathol Res Pract. 2006;202(10):745-50
pubmed: 16884858
Pathol Res Pract. 2016 Mar;212(3):222-5
pubmed: 26839157
Ultrastruct Pathol. 2016;40(2):121-4
pubmed: 27031178
Acta Neuropathol. 2011 Aug;122(2):253-8
pubmed: 21590491
Acta Neuropathol. 2005 Jul;110(1):97-9
pubmed: 15973544
Acta Neuropathol. 2017 Oct;134(4):521-535
pubmed: 28821944
Am J Surg Pathol. 2002 Aug;26(8):1048-55
pubmed: 12170092
Surg Neurol Int. 2011;2:116
pubmed: 21886889
Am J Surg Pathol. 2005 Feb;29(2):247-53
pubmed: 15644783
Folia Neuropathol. 2010;48(3):175-84
pubmed: 20925001
Pituitary. 2015 Feb;18(1):150-8
pubmed: 24823438
Neuropathology. 2017 Dec;37(6):535-543
pubmed: 28631277
Pituitary. 2011 Dec;14(4):367-70
pubmed: 19241173
Mol Med Rep. 2015 Jul;12(1):871-6
pubmed: 25777996